Merck’s New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL (posaconazole) Receives FDA Priority Review

19-11-2013 Business Wire HealthComments (0)

Merck & CoNoxafilPharmaceutical

New Drug Application for an investigational intravenous (IV) solution formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for priority review by the U.S.FDA.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top